Tag archive for ‘Lou Gehrig’s disease’
Neuralstem: Dr. Eva Feldman’s Latest Presentation on The Use of CUR’s Stem Cells in ALS (CUR, Buy, $4.04)
Overview Dr. Eva Feldman is the lead investigator for the clinical trials of Neuralstem’s (CUR) NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). She spoke at the Keystone Symposia on April 9, 2014. Dr. Feldman is the recent President of the American Neurological Association. She is […]
Neuralstem (CUR, Buy, $4.48) Publishing of Phase 1 Results in Annals of Neurology Causes Price Surge (Paid Subscribers Only)
Introduction The final results of the phase 1 trial of Neuralstem’s (CUR) NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) were just published in the peer-reviewed journal, Annals of Neurology. The market has responded very positively to the data with the stock up about 15% to $4.48. […]
Neuralstem: Evidence Increasingly Suggests its Neural Stem Cells are Effective in ALS (CUR, $2.57)
Thoughts on the Stock Price I have been recommending Neuralstem (CUR) since my initiation report of November 5, 2012 at a price of $0.92. The stock has appreciated significantly over the past year and has been extremely strong in the month of September as the price increased from $1.60 on the 4th to a close of $2.68 […]